A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Phase 2 Recruiting 180 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).

Timeline

Start: 2026-01-20
Primary completion: 2026-11-19
Completion: 2028-02-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-95597528	Unknown	—	Subcutaneous

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Summary

Timeline

Drugs

Indications